SAN FRANCISCO, Sept. 15, 2011 /PRNewswire/ -- The Liver Meeting® is the premier meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies.
Approximately 10 percent of Americans have some form of liver disease, but fortunately, the research community has made great strides in recent years in developing new treatments for patients.
At this year's meeting, 2312 abstracts addressing these issues that will be presented, including 276 abstracts that will be presented in oral sessions. Those abstracts are available to members of the press at our website (www.aasld.org).
San Francisco, CA: November 5 – 8, 2011
An AASLD President's press conference highlighting key abstracts and issues presented at the Liver Meeting® is scheduled for Saturday, November 5 at 4:00 pm.
Two of this year's programs deal directly with the direct-acting antiviral agents that were recently approved by the FDA.
Founded in 1950, AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD has grown into an international society responsible for all aspects of hepatology, and our annual meeting attracts more than 8,000 physicians, surgeons, researchers, and allied health professionals from around the world.
Please contact AASLD at 703-299-9766 for information about the above presentations, or to receive any additional information about The Liver Meeting® – or visit our website at www.aasld.org.
Please contact Gregory Bologna to register as press for the meeting: 703-299-9766 or firstname.lastname@example.org.
Image to accompany this story: Liver meeting ad
This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.
|SOURCE American Association for the Study of Liver Diseases (AASLD)|
Copyright©2010 PR Newswire.
All rights reserved